JP7693670B2 - バイオマーカーとしての細胞外遊離ヌクレオソームの使用 - Google Patents

バイオマーカーとしての細胞外遊離ヌクレオソームの使用 Download PDF

Info

Publication number
JP7693670B2
JP7693670B2 JP2022532782A JP2022532782A JP7693670B2 JP 7693670 B2 JP7693670 B2 JP 7693670B2 JP 2022532782 A JP2022532782 A JP 2022532782A JP 2022532782 A JP2022532782 A JP 2022532782A JP 7693670 B2 JP7693670 B2 JP 7693670B2
Authority
JP
Japan
Prior art keywords
cancer
subject
histone
vascular
nucleosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022532782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503379A5 (https=
JP2023503379A (ja
Inventor
ビンセント ミカレフ ジャコブ
ウィルソン‐ロブレス ヘザー
エドワード エクルストン マーク
シャンタル アンドレー ヘルツォーク マリエール
ブラッドリー テレル ジェイソン
Original Assignee
ベルジアン ボリション エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベルジアン ボリション エスアールエル filed Critical ベルジアン ボリション エスアールエル
Publication of JP2023503379A publication Critical patent/JP2023503379A/ja
Publication of JP2023503379A5 publication Critical patent/JP2023503379A5/ja
Priority to JP2025093848A priority Critical patent/JP2025124845A/ja
Application granted granted Critical
Publication of JP7693670B2 publication Critical patent/JP7693670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022532782A 2019-12-02 2020-12-02 バイオマーカーとしての細胞外遊離ヌクレオソームの使用 Active JP7693670B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093848A JP2025124845A (ja) 2019-12-02 2025-06-05 バイオマーカーとしての細胞外遊離ヌクレオソームの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962942596P 2019-12-02 2019-12-02
US62/942,596 2019-12-02
US202063088408P 2020-10-06 2020-10-06
US63/088,408 2020-10-06
PCT/EP2020/084328 WO2021110776A1 (en) 2019-12-02 2020-12-02 Use of cell free nucleosomes as biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093848A Division JP2025124845A (ja) 2019-12-02 2025-06-05 バイオマーカーとしての細胞外遊離ヌクレオソームの使用

Publications (3)

Publication Number Publication Date
JP2023503379A JP2023503379A (ja) 2023-01-27
JP2023503379A5 JP2023503379A5 (https=) 2023-12-11
JP7693670B2 true JP7693670B2 (ja) 2025-06-17

Family

ID=73698838

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022532782A Active JP7693670B2 (ja) 2019-12-02 2020-12-02 バイオマーカーとしての細胞外遊離ヌクレオソームの使用
JP2025093848A Pending JP2025124845A (ja) 2019-12-02 2025-06-05 バイオマーカーとしての細胞外遊離ヌクレオソームの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093848A Pending JP2025124845A (ja) 2019-12-02 2025-06-05 バイオマーカーとしての細胞外遊離ヌクレオソームの使用

Country Status (15)

Country Link
US (1) US20230003735A1 (https=)
EP (2) EP4435431A3 (https=)
JP (2) JP7693670B2 (https=)
KR (1) KR102930652B1 (https=)
CN (1) CN114829939B (https=)
AU (1) AU2020395504A1 (https=)
BR (1) BR112022010774A2 (https=)
CA (1) CA3163181A1 (https=)
ES (1) ES2988371T3 (https=)
IL (1) IL293342B1 (https=)
MX (1) MX2022006655A (https=)
PL (1) PL4070111T3 (https=)
TW (1) TWI902730B (https=)
WO (1) WO2021110776A1 (https=)
ZA (1) ZA202205916B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2820129A1 (en) * 2012-03-02 2015-01-07 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP3736344A1 (en) 2014-03-13 2020-11-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
JP2024542996A (ja) 2021-10-29 2024-11-19 ベルジアン ボリション エスアールエル 均一系免疫アッセイ法
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
EP4490323A1 (en) 2022-03-11 2025-01-15 Belgian Volition SRL Differential diagnosis method
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin
EP4639173A1 (en) * 2022-12-19 2025-10-29 Belgian Volition SRL Calibration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536849A (ja) 2015-10-21 2018-12-13 ベルジアン ボリション エスピーアールエル ヒストン修飾及びバリアントを含むヌクレオソームを検出するための方法
WO2019169263A1 (en) 2018-03-01 2019-09-06 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
GB0413732D0 (en) * 2004-06-13 2004-07-21 Chroma Therapeutics Ltd Histone modification
ATE534908T1 (de) * 2009-08-03 2011-12-15 Universitaetsklinikum Freiburg Verfahren und verbindungen zur diagnose und behandlung von krebs
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115099D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes
PT2788767T (pt) 2011-12-07 2017-12-06 Belgian Volition Sprl Método de detecção de adutos de nucleosoma
EP2820129A1 (en) * 2012-03-02 2015-01-07 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9388213B2 (en) * 2012-09-10 2016-07-12 The Rockefeller University Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof
CN107209190B (zh) * 2014-10-29 2021-07-16 比利时意志有限责任公司 用于富集循环肿瘤dna的方法
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536849A (ja) 2015-10-21 2018-12-13 ベルジアン ボリション エスピーアールエル ヒストン修飾及びバリアントを含むヌクレオソームを検出するための方法
WO2019169263A1 (en) 2018-03-01 2019-09-06 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nucleosomes in Serum of Patients with Benign and Malignant Diseases，International Journal of Cancer，2001年，Vol.95, No.2，pp,114-120，DOI: 10.1002/1097-0215(20010320)95:2<114::aid-ijc1020>3.0.co;2-q

Also Published As

Publication number Publication date
EP4070111A1 (en) 2022-10-12
MX2022006655A (es) 2022-09-07
KR102930652B1 (ko) 2026-02-25
TW202134654A (zh) 2021-09-16
IL293342B1 (en) 2026-01-01
AU2020395504A1 (en) 2022-06-23
ES2988371T3 (es) 2024-11-20
CA3163181A1 (en) 2021-06-10
US20230003735A1 (en) 2023-01-05
EP4070111B1 (en) 2024-08-21
BR112022010774A2 (pt) 2022-08-23
KR20220110794A (ko) 2022-08-09
JP2025124845A (ja) 2025-08-26
JP2023503379A (ja) 2023-01-27
PL4070111T3 (pl) 2025-02-03
EP4435431A3 (en) 2024-10-16
EP4435431A2 (en) 2024-09-25
CN114829939B (zh) 2025-10-21
CN114829939A (zh) 2022-07-29
IL293342A (en) 2022-07-01
WO2021110776A1 (en) 2021-06-10
TWI902730B (zh) 2025-11-01
ZA202205916B (en) 2024-09-25
EP4070111C0 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
JP7693670B2 (ja) バイオマーカーとしての細胞外遊離ヌクレオソームの使用
KR102442803B1 (ko) 결장직장암에 대한 복합 테스트
EP3963330B1 (en) Method for the detection of prostate cancer
US20240019432A1 (en) Diagnostic method for multiple sclerosis
US20240077487A1 (en) Method for the detection of lung cancer
EA047224B1 (ru) Применение бесклеточных нуклеосом в качестве биомаркеров
HK40085725B (en) Use of cell free nucleosomes as biomarkers
HK40085725A (en) Use of cell free nucleosomes as biomarkers
EP4720677A1 (en) Use of cell free nucleosomes as biomarkers
EP3963331A1 (en) Method for the detection of cancer
WO2024223947A1 (en) Use of cell free nucleosomes as biomarkers of carcinomas
WO2025008388A1 (en) Method for the detection of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250605

R150 Certificate of patent or registration of utility model

Ref document number: 7693670

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150